ArticleNeuro-oncology advances
Epigenetic maintenance of the injury response state in glioblastoma stem cells.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glioblastoma stem cells as carriers of tumour memory: a strategy for personalised immunotherapy using tumour-infiltrating lymphocytes.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma (GBM) is a common and highly lethal type of primary brain tumor in adults. Therapeutic failure is partly attributed to a fraction of glioblastoma stem cells (GSCs) that show high levels of heterogeneity and plasticity. Glioblastoma stem cells exist in a transcriptional gradient between 2 states: Developmental (Dev) and injury response (IR), in which IR-GSCs exhibit more invasive behaviors. While previous studies have identified fitness genes in GSCs, the genes required to establish and maintain the Dev and IR states remain poorly defined. Methods: To identify the regulators of the IR-GSC state, we performed a phenotypic genome-wide CRISPR-Cas9 knockout screen in patient-derived GSCs based on cell surface expression of the IR marker CD44. Validation of EP300 in regulation of IR state was performed using CRISPR gene editing and A-458 inhibitor treatment. RNA-seq, CUT&RUN, invasion assays, sphere-forming assays, and a mouse GBM model were used to characterize the phenotypic consequences of EP300 perturbation. Results: We found that perturbation of the histone acetyltransferase EP300 led to decreased CD44 cell surface expression, and loss of IR transcriptional state identity through dysregulation of the epigenome. Functional studies demonstrated that this loss of state identity coincides with decreased self-renewal and invasion in GSCs and delayed tumor initiation and progression in a mouse GBM model. Conclusion: Collectively, our results establish EP300 as a key regulator of IR state identity in GSCs and provide a mechanistic basis for therapeutic targeting of aggressive cellular states in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.